DirectRx is an independent pharmacy dedicated to providing patients with unparalleled, personalized pharmaceutical care. At DirectRx Pharmacy, the patient, physician and pharmacy form a circle of integrated services and coordinated care. There are no gaps in patient care between physician and pharmacy, because we believe that collaboration and communication are critical to creating favorable treatment outcomes. Our sense of urgency and commitment to unparalleled customer care makes DirectRx unique in the marketplace. We are large enough to provide the full range of pharmaceutical solutions and medications required to optimally treat chronic disease states, yet small enough to care that each patient stays on their prescribed regimen and receives the support they need throughout the course of their treatment. We believe in innovative ideas. Breaking traditional methods, DirectRx has an integration of care between the patient and the provider including a support system for the patient, from help with financial assistance to expert advice on how to manage the complicated drug regimens. DirectRx is accredited by NABP, ACHC, URAC and WBENC. Unlike other pharmacies, DirectRx is owned and operated by certified doctors of pharmacy. As a family-owned business, the company has grown to serve more than 20 states since its inception more than two decades ago. Investments in technology help to provide clients with accurate, timely orders at competitive prices. DirectRx is led by founder and CEO Santa Zawaideh, R.Ph., who has been in private, independent practice since 1980. She is the proud recipient of the Michigan Pharmacist Association`s Governor`s Award and former two-term president of the Oakland County Pharmacy Association. Vice President of Clinical Services Amanda Berishaj, Pharm. D., daughter of Zawaideh, oversees the daily operations of DirectRx, as well as the clinical operations of patients with chronic disease states.
Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on bringing life saving treatment to millions of people affected by acute central nervous system conditions -- including stroke and traumatic brain injury as well as other ischemic injuries and neurological disorders such as subarachnoid hemorrhage and spinal cord injury.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis` product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and knowhow related to the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis` business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA.
Merck Frosst Canada is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
bellatrx is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.